Section Arrow
Quote
ANIP.NASDAQ
- ANI Pharmaceuticals
Quotes are at least 15-min delayed:2026/06/30 04:18 EDT
Pre Market
Last
 --
-- (--)
Bid
33.81
Ask
92
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 84.115
-0.385 (-0.46%)
Day High 
85.2499 
Prev. Close
84.5 
1-M High
85.435 
Volume 
315.57K 
Bid
33.81
Ask
92
Day Low
83.48 
Open
84.65 
1-M Low
73.54 
Market Cap 
1.92B 
Currency 美元 
P/E 21.61 
%Yield -- 
10-SMA 82.1 
20-SMA 80.56 
50-SMA 80.59 
52-W High 99.5 
52-W Low 62.605 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.91/9.48
Enterprise Value
2.52B
Balance Sheet
Book Value Per Share
24.73
Cash Flow
Cash Flow Yield
0.11
Income Statement
Total Revenue
883.37M
Operating Revenue Per Share
19.77
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
UPCUniverse Pharmaceuticals Inc12.18+9.22+311.49%-- 
Pre Market 9.06 -3.12 -25.62%
HIMSHims & Hers Health33.39-0.55-1.62%-- 
Pre Market 33.03 -0.36 -1.08%
HLNHaleon plc9.33+0.09+0.97%18.92PE
Pre Market 9.35 +0.02 +0.21%
VTRSViatris16.23-0.1-0.61%-- 
Pre Market 16.62 +0.39 +2.40%
BCRXBioCryst Pharmaceuticals9.55-0.39-3.92%-- 
Pre Market 9.56 +0.01 +0.10%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology,rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically,it generates maximum revenue from the United States, followed by other markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.